Frequently asked questions
In 2022, the global Infectious Disease Therapeutics Market is expected to be worth USD 115845.9 million.
The Infectious Disease Therapeutics Market is estimated to increase at a CAGR of 5.00% between 2023 and 2030, reaching USD 171157.1 Million in 2030.
The hospital segment had the biggest revenue share of 54.5% in 2022
Marketed Products has the biggest market demand in the Infectious Disease Therapeutics Market
The clinics and outpatient centers segment is predicted to grow at the fastest CAGR.
North America was the market leader in 2022, accounting for 39.9% of total revenue.
The top players include Pfizer Inc. (U.S.), Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K), Merck & Co. (U.S.), F. Hoffmann-La AstraZeneca (U.K) and Mylan N.V. (U.S.).
The primary drivers of the market are the increasing frequency of infectious diseases worldwide, advancements in medical technology and treatment options, and growing awareness about the need of early diagnosis and treatment.
The high expense of developing and producing novel treatments The market faces obstacles such as stringent regulatory standards and licensing processes, as well as the issue of tackling a varied variety of infectious diseases with varying treatment techniques.
Biotechnology and genetics advancements for tailored and precise medicines, Increasing research and development investments and Collaborations between pharmaceutical corporations and academic institutions for field innovation are a business opportunity.